Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab

Eye (Basingstoke)

Volumn 28, Issue 3, 2014, Pages 269-278

  Channa, R ^a   Sophie, R ^a   Khwaja, A A ^a   Do, D V ^a,b   Hafiz, G ^a   Nguyen, Q D ^a,b   Campochiaro, P A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anti VEGF; Diabetic macular edema; Macular edema; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; ATROPHY; CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOVEAL ATROPHY; HUMAN; LASER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINA FOVEA; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84896356110     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.245     Document Type: Article

References (12)

1. Klein R, Klein B. Vision disorders in diabetes. In: Group NDD editor, Diabetes in America, 2nd ed. National Institutes of Health: Washington, DC, USA, 1995, pp 293-330.
2. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
3. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2009; 116: 2175-2181.
4. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
5. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmolgy 2010; 117: 1064-1077.
6. Massin P, Bandello F, Hansen LL, Harding SP, Larsen M, Mitchell P et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care 2010; 33: 2399-2405.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Masin P, Schlingemann RO et al. The RESTORE Study. Ranibizumab monotherapy or combined with laser vs laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
8. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema. Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
9. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013; 131(2): 139-145.
10. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008; 28: 957-963.
11. Jonas JB, Martus P, Degenring RF, Kreissing I, Akkoyun I. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 2005; 123: 1338-1343.
12. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010; 117: 946-953.